Advances in the use of nanoparticles for specific cell-target delivery of anti-cancer agents

IF 5.2 2区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL
Ana Belen Diaz-Ruano , Eliana Gomez-Jimenez , Gloria Llamas-Jimenez , Arena Ramirez-Muñoz , Pablo Espejo-Hijano , Alfonso Rubio-Navarro , Manuel Picon-Ruiz
{"title":"Advances in the use of nanoparticles for specific cell-target delivery of anti-cancer agents","authors":"Ana Belen Diaz-Ruano ,&nbsp;Eliana Gomez-Jimenez ,&nbsp;Gloria Llamas-Jimenez ,&nbsp;Arena Ramirez-Muñoz ,&nbsp;Pablo Espejo-Hijano ,&nbsp;Alfonso Rubio-Navarro ,&nbsp;Manuel Picon-Ruiz","doi":"10.1016/j.lfs.2025.123604","DOIUrl":null,"url":null,"abstract":"<div><div>In recent decades, cancer has emerged as one of the leading causes of death in developed countries. To revert this progression, scientists have focused on the design of new strategies for early detection of this disease and the development of more effective treatments for its eradication. Regarding the latter, one of the main research efforts has been directed toward designing more specific delivery systems for the administration of anti-tumoral agents. In this sense, the efficacy of conventional therapies used for cancer treatment, such as chemotherapy, immune checkpoint inhibitors and radiation therapy, are often limited by their lack of specificity and their potential to cause adverse secondary effects on healthy tissues. Therefore, designing specific cell-targeted delivery systems for anti-tumoral agents presents a promising approach to overcoming the limitations of conventional cancer therapies. In this review we summarize the advances in the use of nanoparticles for Specific Cell-Target Delivery of anti-tumoral agents from in vitro to clinical studies.</div></div>","PeriodicalId":18122,"journal":{"name":"Life sciences","volume":"371 ","pages":"Article 123604"},"PeriodicalIF":5.2000,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Life sciences","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0024320525002383","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

In recent decades, cancer has emerged as one of the leading causes of death in developed countries. To revert this progression, scientists have focused on the design of new strategies for early detection of this disease and the development of more effective treatments for its eradication. Regarding the latter, one of the main research efforts has been directed toward designing more specific delivery systems for the administration of anti-tumoral agents. In this sense, the efficacy of conventional therapies used for cancer treatment, such as chemotherapy, immune checkpoint inhibitors and radiation therapy, are often limited by their lack of specificity and their potential to cause adverse secondary effects on healthy tissues. Therefore, designing specific cell-targeted delivery systems for anti-tumoral agents presents a promising approach to overcoming the limitations of conventional cancer therapies. In this review we summarize the advances in the use of nanoparticles for Specific Cell-Target Delivery of anti-tumoral agents from in vitro to clinical studies.

Abstract Image

纳米颗粒在抗癌药物特异性细胞靶向递送中的应用进展
近几十年来,癌症已成为发达国家的主要死亡原因之一。为了逆转这一进程,科学家们专注于设计早期发现这种疾病的新策略,并开发更有效的治疗方法来根除这种疾病。关于后者,主要的研究工作之一是为抗肿瘤药物的施用设计更具体的递送系统。从这个意义上说,用于癌症治疗的常规疗法,如化疗、免疫检查点抑制剂和放射疗法的疗效往往受到限制,因为它们缺乏特异性,而且可能对健康组织造成不良的继发性影响。因此,设计抗肿瘤药物的特异性细胞靶向递送系统是克服传统癌症治疗局限性的一种有希望的方法。在这篇综述中,我们总结了从体外到临床研究中使用纳米颗粒特异性细胞靶向递送抗肿瘤药物的进展。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Life sciences
Life sciences 医学-药学
CiteScore
12.20
自引率
1.60%
发文量
841
审稿时长
6 months
期刊介绍: Life Sciences is an international journal publishing articles that emphasize the molecular, cellular, and functional basis of therapy. The journal emphasizes the understanding of mechanism that is relevant to all aspects of human disease and translation to patients. All articles are rigorously reviewed. The Journal favors publication of full-length papers where modern scientific technologies are used to explain molecular, cellular and physiological mechanisms. Articles that merely report observations are rarely accepted. Recommendations from the Declaration of Helsinki or NIH guidelines for care and use of laboratory animals must be adhered to. Articles should be written at a level accessible to readers who are non-specialists in the topic of the article themselves, but who are interested in the research. The Journal welcomes reviews on topics of wide interest to investigators in the life sciences. We particularly encourage submission of brief, focused reviews containing high-quality artwork and require the use of mechanistic summary diagrams.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信